XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation - Adoption of New Revenue Recognition Standard Revenue Impacted Previously Reported (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Jun. 30, 2018
Consolidated Statements of Operations:            
Total revenue $ 216.8   $ 187.9 [1] $ 419.1 $ 366.7 [1]  
Selling, general, and administrative expense 135.2   107.4 [1] 265.1 214.6 [1]  
Income tax provision 1.0   (25.3) [1] 2.6 (20.8) [1]  
Net income attributable to Myriad Genetics, Inc. stockholders $ 2.6 $ (0.7) $ 30.9 [1] $ 1.9 $ 109.7 [1]  
Earnings per share:            
Basic $ 0.04   $ 0.45 [1] $ 0.03 $ 1.59 [1]  
Diluted $ 0.03   $ 0.43 [1] $ 0.02 $ 1.54 [1]  
Consolidated Statements of Cash Flows:            
Net income attributable to Myriad Genetics, Inc. stockholders $ 2.6 $ (0.7) $ 30.9 [1] $ 1.9 $ 109.7 [1]  
Trade accounts receivable       (0.9) (13.0) [1]  
Consolidated Balance Sheet:            
Trade accounts receivable 116.6     116.6   $ 99.5 [1]
Retained earnings $ 22.9     $ 22.9   54.1 [1]
ASC 606 | As Previously Reported            
Consolidated Statements of Operations:            
Total revenue     192.7   380.6  
Selling, general, and administrative expense     115.2   230.4  
Income tax provision     (26.2)   (21.4)  
Net income attributable to Myriad Genetics, Inc. stockholders     $ 28.8   $ 108.4  
Earnings per share:            
Basic     $ 0.42   $ 1.57  
Diluted     $ 0.40   $ 1.52  
Consolidated Statements of Cash Flows:            
Net income attributable to Myriad Genetics, Inc. stockholders     $ 28.8   $ 108.4  
Trade accounts receivable         (32.5)  
Consolidated Balance Sheet:            
Trade accounts receivable           98.3
Retained earnings           52.9
ASC 606 | Adjustments            
Consolidated Statements of Operations:            
Total revenue     (4.8)   (13.9)  
Selling, general, and administrative expense     (7.8)   (15.8)  
Income tax provision     0.9   0.6  
Net income attributable to Myriad Genetics, Inc. stockholders     $ 2.1   $ 1.3  
Earnings per share:            
Basic     $ 0.03   $ 0.02  
Diluted     $ 0.03   $ 0.02  
Consolidated Statements of Cash Flows:            
Net income attributable to Myriad Genetics, Inc. stockholders     $ 2.1   $ 1.3  
Trade accounts receivable         $ (19.5)  
Consolidated Balance Sheet:            
Trade accounts receivable           1.2
Retained earnings           $ 1.2
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.